The consortium serves as a bridge between academic discovery and commercial application, focusing on the development of highly reproducible human-relevant models. By integrating its proprietary Vertical-Wheel bioreactor platform, PBS Biotech aims to solve systemic manufacturing bottlenecks. The technology provides a low-shear hydrodynamic environment, which is critical for maintaining cell quality and aggregate integrity during the transition from benchtop development to GMP-grade production.
PBS Biotech Joins Organoid COMMONS to Scale Human-Relevant Models
Camarillo-based PBS Biotech has joined the Organoid COMMONS consortium, aiming to transition complex organoid technologies from laboratory research into large-scale industrial manufacturing. The partnership seeks to establish standardized bioprocessing frameworks that move the pharmaceutical industry beyond its traditional reliance on animal-based testing models.
Martin Simonetti, CEO of PBS Biotech, stated that the collaboration is designed to define benchmark standards for the next generation of regenerative medicine. Beyond individual technical contributions, the company will participate in building a shared repository of process knowledge and standardized protocols. This effort is expected to benefit the broader life sciences sector by reducing batch-to-batch variability and improving the overall viability of organoid yields in precision medicine.
Comments (0)
No comments yet. Be the first!